Citations

Clear

2960 citation(s) found for "Kim, P".

Impaired vaccine-elicited humoral protection in sepsis surviving hosts 3760
Kozurek, Emma , Kucaba, Tamara A., Kim, Caleb Y. , Skon-Hegg, Cara , Knoop, Kathryn A. , Badovinac, Vladimir P , Griffith, Thomas S.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1525 Get It

Abstract Description Sepsis, the life-threatening organ dysfunction stemming from the severe inflammatory response to systemic microbial infection, can affect humans of any age. One consequence of sepsis is the development of prolonged immunoparalysis that contributes to increased susceptibility to infection. With vaccination being an important means for protecting humans from infection throughout their lifetime, it is surprising that there has been no study performed to date assessing vaccine efficacy in sepsis survivors. We found neonatal and adult mice given an intramuscularly delivered inactivated multivalent influenza vaccine 30 days after sepsis induction had reduced total and class switched Ab titers, compared to non-septic controls. The reduced humoral response was due, in part, to impaired CD4 T cell and B cell responses to the vaccine. Reduced Ab titers were similarly seen in post-septic mice given an intranasal live-attenuated influenza vaccine. ELISpot data demonstrating reduced numbers of antibody secreting cells in the spleens of vaccinated septic mice further support the ELISA results. Moreover, mice vaccinated prior to sepsis induction also showed reduced antibody titers. Importantly, vaccinated septic mice had reduced protection to a lethal influenza challenge, demonstrated by increased mortality and viral burden in the lungs. These data collectively show how sepsis can lead to increased susceptibility to pathogens normally neutralized by vaccine-induced immunity. Funding Sources Supported by NIH/NIAID R35 GM140881; 5R01 GM139046; 1T32TR004385 Topic Categories Translational and Interventional Immunology (TI)
Extracellular vesicle-mediated antitumor immunity in response to radiotherapy 4827
Uzendu, Chisom, Lavoie, Roxane R. , Lucien-Matteoni, Fabrice, Kim, Yohan , Dong, Haidong , Lucien, Fabrice

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2444 Get It

Abstract Description Combination of radiotherapy (RT) and immunotherapy has gained popularity to turn up the heat on cold tumors. However, intrinsic resistance is prevalent, hence better therapeutic strategies are needed to improve the outcome of patients. We recently demonstrated in metastatic prostate cancer that circulating levels of tumor-derived extracellular vesicles (tdEVs) increased shortly after RT and was associated with poor survival. TdEVs are mediators of antitumor immunity but their role in response to RT remains unknown. Our study elucidates the impact of RT on immunomodulatory roles of tdEVs. Mouse tumors models expressing a bioluminescent EV reporter were treated with clinically used doses of RT. TdEV organotropism was measured by ex-vivo imaging at different timepoints. TdEVs were detected in blood, spleen, lymph nodes and immune cells. OT-1 transgenic mice and in vitro co-culture assays showed a reduction in CD8 T-cell cytotoxic activity in presence of tdEVs from irradiated cells. To identify key players of tdEV-mediated immunosuppression in response to RT, proteomic analysis revealed the immune checkpoint molecule B7-H3 was overexpressed in tdEVs after irradiation. Genetic deletion of B7-H3 inhibited the suppressive activity of tdEVs from irradiated cells resulting in enhanced T-cell cytotoxicity. This study describes tdEVs as a mediator of systemic immunosuppression in response to radiotherapy and B7-H3 as a potential therapeutic target to boost antitumor immunity. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
B cells expressing SIRPα are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma 2786
Tang, Xinyi , Bhardwaj, Vaishali , Mukherjee, Prithviraj , Novak, Anne J. , Ansell, Stephen M. , Bhardwaj, Vaishali , Yang, Zhi-Zhang , Kim, Hyo Jin , Novak, Joseph P. , Villasboas, José C. , Mondello, Patrizia

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.668 Get It

Abstract Description Signal regulatory protein-α (SIRPα) is a key member of the “do-not-eat-me” signaling pathway and is expressed on intratumoral monocytes/macrophages in lymphoma. In this study, we found that SIRPα is also expressed by a subset of malignant B cells in lymphoma. SIRPα+ B cells have a memory phenotype with germinal center (GC) dark-zone features, and RNA velocity analysis showed that SIRPα+ B cells exhibit higher spliced transcripts confirming a more mature phenotype. SIRPα expression is substantially upregulated by treating lymphoma B cells with LPS or CpG and SIRPα+ B cells showed increased proliferation when compared to SIRPα- B cells, which was associated with reduced cellular autophagy. SIRPα+ B cells exhibited increased expression of BAFF signaling pathway molecules as the likely mechanism of increased proliferation and survival. Furthermore, in co-culture, SIRPα+ lymphoma B cells suppressed T-cell function and blocking SIRPa/CD47 signaling reversed T cell inhibition. Clinically, we found that a greater number of SIRPα+ B cells present in the diagnostic tumor biopsies of FL patients was associated with a significantly poorer overall survival. We conclude that SIRPα+ lymphoma B cells are a proliferative component of indolent lymphomas, are associated with T-cell suppression, and increased prevalence of these cells is associated with a poor prognosis. Targeting SIRPα+ B cells in lymphoma may therefore be a promising therapeutic strategy. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Cytokine-inducible SH2-containing protein (CISH) is an intracellular immune checkpoint that controls T regulatory cells in Splenic Marginal Zone Lymphoma 2122
Tang, Xinyi , Yang, Zhi-Zhang, Yu, Yue , Wu, Xiaosheng, Bhardwaj, Vaishali , Mukherjee, Prithviraj , Kim, Hyo Jin , Novak, Anne J. , Ansell, Stephen M. , Bhardwaj, Vaishali , Mondello, Patrizia

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.085 Get It

Abstract Description The efficacy of immunotherapy for splenic marginal zone lymphoma (SMZL) remains limited due to the strong immune suppression present in the tumor microenvironment (TME). Tregs play a key role in maintaining TME homeostasis by suppressing effector T cells and malignant B cells. Previously, we identified two Treg subsets CD26+ and CD161+ in SMZL. CD161+ Tregs were more effective at suppressing both CD8+T cells and malignant B cells, whereas CD26+Tregs primarily inhibited CD8+T cells. Patients with higher levels of CD26+ Tregs and fewer CD161+ Tregs tend to have worse outcomes. In this study, we found that cytokine-inducible SH2-containing protein (CISH), a known negative regulator of immune activation, is highly expressed in CD26+Tregs compared to CD161+ Tregs. Co-culturing B cells enhanced the expression of CISH and CD26 in CD4+CD25- Treg cells, knockdown of CISH in Tregs reduced CD26 expression and their immune suppression activity of CD8+T cells, while CRISPR knockout of CISH in Karpas 299 cells led to higher expression CD70, a molecule associated with less immunesuppression. Our findings suggest that increased CISH expression in Tregs could result in increased immune suppression and unfavorable outcome in SMZL, suggesting CISH is a potential therapeutic tagrget in SMZL by dempening immunosuppressive property of the Treg cells hence boosting the antitumor immunity. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Impact of Facial Surgery Scars on Quality-of-Life: Perspectives of East Asian and White Patients
Garg, Stuti P. , Wan, Rou , Shah, Krish V., Adam, Tarifa H. , Kim, John Y., Galiano, Robert D. , Galiano, Robert D , Reddy, Narainsai K. , Shah, Krish V., Ellis, Marco F.

Mayo Clinic

Journal of Craniofacial Surgery | November 20, 2025 | Volume: 37 | Issue: 3/4 | Pages: 522-525

10.1097/scs.0000000000012216 | PMID 41263428 Get It

Background: Inappropriate facial scarring can lead to significant physical and psychosocial morbidity. There is a need to better understand how scar perception varies across ethnic groups, and how it impacts broader quality-of-life domains such as career and sexual well-being. This study evaluates White and Asian patients’ perceptions of facial scars related to symptoms, appearance, psychosocial health, and career/sexual well-being. Methods: Facial surgery patients from 5 providers were recruited to complete the SCAR-Q and Career/Sexual Well-Being (CS) scales through phone or email. Higher scores on both assessments indicate more positive patient perceptions. Results: Among the 147 respondents, 50.3% were Asian and 49.7% were White. Procedures included blepharoplasty (n=56), rhinoplasty (n=20), eyelid revision (n=19), facelift (n=18), Mohs surgery (n=7), chin augmentation (n=6), craniotomy (n=6), and other facial procedures (n=16). White patients scored significantly higher than Asian patients on the SCAR-Q total (median=260 versus 234), appearance (76 versus 59), psychosocial (100 versus 87), and CS (16 versus 12.5) scales ( P =0.004, P <0.001, P =0.026, and P <0.001, respectively). Symptom scores positively correlated with time since surgery in both groups (Asian: r =0.326, P =0.004; White: r =0.319, P =0.011). Conclusions: Asian patients reported more negative perceptions of scar appearance, symptoms, psychosocial impact, and career/sexual well-being than White patients. These findings underscore the importance of tailored follow-up care and counseling to address ethnic differences in scar perception and quality-of-life outcomes.
Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026) Part I: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 113-123

10.1097/ju.0000000000004842 | PMID 41263323 Get It

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part III: Treatment of Patients With Kidney and/or Ureteral Stones and Future Directions
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 132-141

10.1097/ju.0000000000004844 | PMID 41263325 Get It

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part II: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 124-131

10.1097/ju.0000000000004843 | PMID 41263322 Get It

Generative AI and Foundation Models in Radiology: Applications, Opportunities, and Potential Challenges
Tavakoli, Neda , Abad, Zahra Shakeri Hossein , Gowda, Vrushab, Samsel, Konrad , Bedayat, Arash , Ghasemiesfe, Ahmadreza , Bagci, Ulas, Hsiao, Albert , Leiner, Tim , Carr, James , Kim, Daniel , Shakeri, Zahra , Rahsepar, Amir Ali , Kim, Daniel , Leiner, Tim , Gowda, Vrushab , Bağcı, Ulaş

Mayo Clinic

Radiology | November 18, 2025 | Volume: 317 | Issue: 2 | Pages: No page available

10.1148/radiol.242961 | PMID 41251552 Get It

Foundation models can streamline imaging workflows, improve diagnostic accuracy, enable personalized treatment, and, via integrated generative artificial intelligence, create synthetic images to augment scarce real-world data; however, successful adoption requires explainability, trust, and workflow integration.